Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Progressive Pulmonary Fibrosis (PPF) Treatment Market Snapshot (2023 to 2033)

The global progressive pulmonary fibrosis (PPF) Treatment market is expected to reach at US$ 3.72 Million in 2023 and is projected to exhibit a CAGR of 7.5% from 2023 to 2033. Several experimental cancer drugs show promise in treating idiopathic pulmonary fibrosis as a potential treatment in the future. Also, key players are increasingly focusing on research and development activity, which will create lucrative growth opportunities in the progressive pulmonary fibrosis (PPF) treatment market.

As the field of image analysis and processing advances, machine learning applications based on deep learning provide new possibilities for the use of radio mics and deep learning in image analysis. It is imperative to develop optimized algorithms in collaboration with appropriate predictors of disease outcomes and to validate radiological biomarkers against those predictors.

In randomized clinical trials, antifibrotic drugs, either nintedanib or pirfenidone, slow the progression of progressive ILD associated with IPF or progressive non-IPF ILD. The clinical management of this subgroup of patients in its current state is beginning to see a new era that offers the perfect opportunity to explore still unexplored territories within the industry.

Data Points Key Statistics
Estimated Base Year Value (2022) US$ 3.5 Million
Expected Market Value (2023) US$ 3.72 Million
Anticipated Forecast Value (2033) US$ 7.7 Million
Projected Growth Rate (2023 to 2033) 7.5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Progressive Pulmonary Fibrosis (PPF) Treatment Demand Analysis vs. Forecast 2023 to 2033

According to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6.3%. Current treatments can prolong the life of pulmonary fibrosis patients by nearly two or five years. Many researchers are currently working to discover the cause and potential treatments for pulmonary fibrosis in developed countries. Innovative therapeutic pathways for pulmonary fibrosis are currently being developed by academic institutions, pharmaceutical firms, and biopharmaceutical companies.

A rise in the number of patients with progressive pulmonary fibrosis (PPF) and the awareness surrounding its treatment is also expected to spur the development of more PPF-related pharmaceutical drugs. The progressive pulmonary fibrosis (PPF) treatment market is expected to grow at a moderate rate due to the complicated reimbursement associated with multiple patent expirations. Researchers around the world are exploring ways to treat the side effects of PPF treatments.

A new study has shown that saracatinib may be effective in treating idiopathic pulmonary fibrosis (IPF). According to a study published in the American Journal of Respiratory and Critical Care Medicine, Saracatinib reduced tissue scarring in preclinical models of IPF similarly to two drugs in clinical trials. Researchers from National Jewish Health, Mount Sinai Ichan School of Medicine, Yale School of Medicine, and AstraZeneca investigated the effectiveness of oral therapy treatments using a novel computational approach. The global demand for progressive pulmonary fibrosis (PPF) treatment is projected to increase at a CAGR of 7.5% during the forecast period between 2023 and 2033, reaching a total of US$ 7.7 Million in 2033.

What Factors are Driving Global Sales of Progressive Pulmonary Fibrosis (PPF) Treatment?

Drug Approvals and New Therapies are Expected to Grow the Market

Manufacturers of pulmonary fibrosis drugs are focusing on building strong pipelines for future launches with better patient compliance. Novel therapies are being developed for pulmonary fibrosis by different manufacturers. According to researchers, pulmonary fibrosis treatment may be accomplished with the launch of some large molecules in the upcoming years. Various research activities and drug approval processes are being conducted by manufacturers of pulmonary fibrosis drugs in various regions to generate revenue.

Technological advances and advances in medical science have led to the development of new and innovative treatments. In addition, this has contributed to the growth of the global market for pulmonary fibrosis treatments. As a result of the high prevalence of pulmonary fibrosis, several institutions have been studying the disease to understand its causes and thus contributed to the growth of the market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Future Growth Prospects of Progressive Pulmonary Fibrosis Treatment Market

Progression therapy for pulmonary fibrosis has promising growth prospects in the future. New hope has been provided for patients suffering from pulmonary fibrosis due to recent breakthroughs in the field. In addition, new medications are being developed, stem cells are being used, new surgical techniques are being developed, and gene therapy is being utilized.

Pneumofibrosis patients can benefit from the development of new medications. A study found that pirfenidone slowed the progression of the condition and improved the overall quality of life of patients. Additionally, biologics have been found to be effective in the treatment of pulmonary fibrosis. Among the many promising treatments for pulmonary fibrosis, stem cell therapy is one of the most promising. The stem cells in the lungs are capable of regenerating tissue, and they can be used to replace damaged tissue. By doing so, oxygenation can be improved and complications can be reduced. There have been promising results in stem cell therapy so far, even though the field is still in its infancy.

MicroRNAs are considered potential targets for treating progressive pulmonary fibrosis in the future. MiRNAs play a key role in regulating different cellular functions, making it essential to understand how they influence inflammatory events causing pulmonary fibrosis to occur. Several clinical and laboratory biomarkers are being investigated in order to form a prediction of which subgroup of patients is most likely to progress or develop lung fibrosis in order to achieve a more accurate prediction.

What are the Challenges Faced by Industry Players to Progressive Pulmonary Fibrosis (PPF) Treatment in the Market?

Insufficient Treatment Options and Associated Disorders Restrict Treatment Options

Managing pulmonary fibrosis presents a limited range of treatment options. In the past, immunosuppressive medications like corticosteroids were commonly used to treat diseases off-label. As a result, Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech introduced Ofev (nintedanib) and Esbriet (pirfenidone), two medications that revolutionized the treatment of pulmonary fibrosis worldwide.

One of the major barriers to the development of treatments for pulmonary fibrosis is the high price of drugs and low per capita spending on the treatment, as well as the inaccessibility of drugs such as Ofev and Esbriet. Poor and middle-income countries are often subject to a delayed diagnosis, which can lead to more comorbidities and complicate illness management. Over 60% of pulmonary fibrosis patients suffer from comorbidities including pulmonary hypertension.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-Wise Insights

What Makes North America the Largest Market for Progressive Pulmonary Fibrosis (PPF) Treatment?

Increasing Treatment Adoption for Progressive Pulmonary Fibrosis (PPF) with New Drug Development

Due to its well-established healthcare system and high awareness of asthma patients, North America is predicted to hold 51% of the global healthcare market by 2023. Currently, North America dominates the market for progressive pulmonary fibrosis treatment. During the forecast period of 2023 to 2033, the region will continue to be a strong contributor.

The persistently increasing number of pulmonary fibrosis patients is driving the North American market for pulmonary fibrosis treatments. Asthma is one of many respiratory diseases that are on the rise in the region at a high rate of prevalence, and those cases are on the rise at an alarming rate. With such a large number of patients in the region, it is expected that the pulmonary fibrosis treatment market will thrive in the near future. In addition, rapidly evolving healthcare infrastructure, along with a growing health awareness in North America, are driving the growth of pulmonary fibrosis treatments.

A new generation of drugs being developed and approved by the FDA in this region is expected to flourish in the market further. For instance, there are two drugs approved by the Food and Drug Administration (FDA) at the moment for treating the most common form of PF, which is known as idiopathic pulmonary fibrosis (IPF). Ofev® and Esbriet® both contain nintedanib (Ofev®). Clinical trials have shown that these drugs slow down lung scarring and fibrosis, so they're called anti-fibrotic agents. Mild, moderate, and severe forms of IPF can be treated with these drugs.

How are Progressive Pulmonary Fibrosis (PPF) Treatments Lucrative in Europe?

Progressive Pulmonary Fibrosis Treatment Demand Grows as Research and Medical Facilities Expand

With a market share of 35% during the forecast period, Europe will dominate the global progressive pulmonary fibrosis (PPF) Treatment market. Research and development activities are growing rapidly in the region, and government grants are being awarded to encourage more such studies. This is expected to lead to promising growth in the pulmonary fibrosis treatment market.

Approximately 29.2% of the European market was dominated by Germany in 2022. A growing geriatric population in Germany continues to drive adoption rates higher. A growing geriatric population, Industrial advancements, and an increase in Research and Development spending all contribute to Germany's progressive pulmonary fibrosis treatment market. Increasing age is associated with a higher risk of pulmonary-related problems that occur in the body. Increasing geriatric populations are a major factor driving demand for pulmonary fibrosis treatment.

Further growth of the market is expected to be driven by the increase in hospitals for the treatment of pulmonary fibrosis and advancements in healthcare technologies and tools. More than 150 clinics in Europe are represented by the German Medical Group. Medical services can be obtained at leading German clinics through the company.

Category-wise Insights

What is the Impact of MAPK Inhibitors on the Progression of the Pulmonary Fibrosis (PPF) Treatment Market?

An increasing Number of Cancer Patients Will Increase Growth at a Significant Rate

Based on the drug class of progressive pulmonary fibrosis (PPF) treatment the market for MAPK inhibitors is expected to grow the market. As the prevalence of cancer rises, the demand for MAPK inhibitors is expected to increase thereby boosting the growth of the market. Pharmaceutical therapeutic targets for pituitary adenomas are also increasing due to the growth in healthcare expenditures. Increasing government funding will also help improve the healthcare infrastructure, further impacting the market dynamics.

In addition to the studies that have been conducted, there has been evidence that the signaling pathway plays a significant role in various types of cancers, such as melanoma and non-small cell lung cancer. As a result, researchers are increasingly interested in targeting the MAPK signaling pathway as a potentially effective cancer treatment option. Researchers and developers have been working on developing MEK inhibitors that inhibit MAPK signaling in this sector. This will all contribute to the growth of the MAPK inhibitor market.

Are Distribution Channels Potentially Stimulating the Market for Progressive Pulmonary Fibrosis (PPF) Treatment?

Treatment of Progressive Pulmonary Fibrosis (PPF) to Gain Traction in Retail Pharmacies

Based on distribution channels, the global market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The revenue share of retail pharmacies of PPF is expected to accumulate a revenue share of 52.6% during the forecast period. 

Currently, prescription drug formulations are easily obtainable and over-the-counter drugs are available at retail pharmacies, driving the market for pulmonary fibrosis treatment. With more in-house pharmacies partnering with outer retail outlets, drug sales have grown in the market. Memberships are growing, and discounts are available for loyal customers which has added further momentum to market growth. Future retail stores that deliver drugs to homes in the locality and accept online drug orders are expected to expand.

The Start-up Ecosystem: What are Start-ups Doing to Secure Future Growth Opportunities?

Some of the start-ups in the progressive pulmonary fibrosis (PPF) treatment market include-

  • ForwoRx Therapeutics is a Canada-based firm that focuses on repurposing and reformulating approved drugs. Therapeutics are being developed by the company for the treatment of chronic diseases associated with fibrosis (progressive scarring), including IPF and PAH). A company has an Oral Dissolving Tablets (ODT) platform that releases therapeutics rapidly under the tongue by dissolving the tablets rapidly under the tongue. A platform based on ODT is also offered by the company.
  • PulmoSIM Therapeutics is a United States firm specializing in therapeutics for progressive and rare respiratory diseases. In addition to PT001, PT002 is being developed for idiopathic pulmonary fibrosis and pulmonary arterial hypertension. BIOiSIM is an artificial intelligence biosimulation platform used by the company to develop drugs.

Market Competition

Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demand. End users will benefit from the use of new products and technologies by promoting them. Strategic partnerships can be formed by companies in order to increase their production capacity.

  • Boehringer Ingelheim published Phase II information on BI 10015550, a new investigational PDE4B inhibitor. It was published in The New England Journal of Medicine (NEJM). An ATS Breaking News session on May 16 in San Francisco will also present promising 12-week results demonstrating a reduction in lung function decline in IPF patients. Globally acclaimed for its pulmonary fibrosis solutions, the company aspires to one day develop a cure for the debilitating chronic disease.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 3.72 Million
Market Value in 2033 US$ 7.7 Million
Growth Rate CAGR 7.5%
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Drug Class
  • Treatment
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • FibroGen
  • Hoffmann-La Roche Ltd
  • Pliant Therapeutics, Inc.
  • United Therapeutics Corporation
  • Galapagos
  • Novartis AG
  • Prometic Life Sciences Inc.
  • Merck & Co., Inc.
Customization Available Upon Request

Key Segments Profiled in the Progressive Pulmonary Fibrosis (PPF) Treatment Market Industry Survey?

By Treatment Type:

  • MAPK Inhibitor
  • Tyrosine Inhibitor
  • Autotaxin Inhibitors

By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Treatment:

  • Self-Care
  • Medicines
  • Pirfenidone
    • Nintedanib
    • Others
  • Lung Transplant
  • Palliative Care

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Potential of Growth in the Market?

Through 2033, the market is anticipated to prosper at a 7.5% CAGR.

What May the Market Size be in 2033?

By 2033, the market is anticipated to be worth about US$ 7.7 million.

How Significant Is the Market Size Presently?

The market is anticipated to clock in at US$ 3.72 million in 2023.

What is the Market Share of Germany?

With 29.2% of the total market, Germany took over the Europe market.

What is the North America Share of the Market?

North America is anticipated to possess 51% of the market by 2023.

What is the Leading Distribution Channel Segment?

Based on the distribution channels, PPF's retail pharmacies acquired a revenue share of 52.6%.

Table of Content

1. Executive Summary | Progressive Pulmonary Fibrosis (PPF) Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. MAPK Inhibitors

        5.3.2. Tyrosine Inhibitors

        5.3.3. Autotaxin Inhibitors

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        6.3.1. Hospital Pharmacies

        6.3.2. Retail Pharmacies

        6.3.3. Online Pharmacies

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        7.3.1. Self-care

        7.3.2. Medicines

            7.3.2.1. Pirfenidone

            7.3.2.2. Nintedanib

            7.3.2.3. Others

        7.3.3. Lung transplant

        7.3.4. Palliative Care

    7.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. Middle East and Africa(MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Distribution Channel

        9.2.4. By Treatment

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distribution Channel

        9.3.4. By Treatment

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Distribution Channel

        10.2.4. By Treatment

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distribution Channel

        10.3.4. By Treatment

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Class

        11.2.3. By Distribution Channel

        11.2.4. By Treatment

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

        11.3.4. By Treatment

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Drug Class

        12.2.3. By Distribution Channel

        12.2.4. By Treatment

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

        12.3.4. By Treatment

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Class

        13.2.3. By Distribution Channel

        13.2.4. By Treatment

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Distribution Channel

        13.3.4. By Treatment

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Class

        14.2.3. By Distribution Channel

        14.2.4. By Treatment

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

        14.3.4. By Treatment

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of Middle East and Africa(MEA)

        15.2.2. By Drug Class

        15.2.3. By Distribution Channel

        15.2.4. By Treatment

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Distribution Channel

        15.3.4. By Treatment

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Class

            16.1.2.2. By Distribution Channel

            16.1.2.3. By Treatment

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Class

            16.2.2.2. By Distribution Channel

            16.2.2.3. By Treatment

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Class

            16.3.2.2. By Distribution Channel

            16.3.2.3. By Treatment

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Class

            16.4.2.2. By Distribution Channel

            16.4.2.3. By Treatment

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Class

            16.5.2.2. By Distribution Channel

            16.5.2.3. By Treatment

    16.6. United Kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Class

            16.6.2.2. By Distribution Channel

            16.6.2.3. By Treatment

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Class

            16.7.2.2. By Distribution Channel

            16.7.2.3. By Treatment

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Class

            16.8.2.2. By Distribution Channel

            16.8.2.3. By Treatment

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Class

            16.9.2.2. By Distribution Channel

            16.9.2.3. By Treatment

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Class

            16.10.2.2. By Distribution Channel

            16.10.2.3. By Treatment

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Class

            16.11.2.2. By Distribution Channel

            16.11.2.3. By Treatment

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Class

            16.12.2.2. By Distribution Channel

            16.12.2.3. By Treatment

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Class

            16.13.2.2. By Distribution Channel

            16.13.2.3. By Treatment

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Class

            16.14.2.2. By Distribution Channel

            16.14.2.3. By Treatment

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Class

            16.15.2.2. By Distribution Channel

            16.15.2.3. By Treatment

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Class

            16.16.2.2. By Distribution Channel

            16.16.2.3. By Treatment

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Class

            16.17.2.2. By Distribution Channel

            16.17.2.3. By Treatment

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Class

            16.18.2.2. By Distribution Channel

            16.18.2.3. By Treatment

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Class

            16.19.2.2. By Distribution Channel

            16.19.2.3. By Treatment

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Class

            16.20.2.2. By Distribution Channel

            16.20.2.3. By Treatment

    16.21. Israel  

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Class

            16.21.2.2. By Distribution Channel

            16.21.2.3. By Treatment

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Class

        17.3.3. By Distribution Channel

        17.3.4. By Treatment

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Boehringer Ingelheim

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Bristol-Myers Squibb

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. FibroGen

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Hoffmann-La Roche Ltd

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Pliant Therapeutics, Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. United Therapeutics Corporation

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Galapagos

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Novartis AG

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Prometic Life Sciences Inc.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Merck & Co., Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 19: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 20: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 23: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 24: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 27: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 28: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 31: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 32: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 18: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 19: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 38: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 39: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 78: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 79: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 82: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 83: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 91: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 92: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 94: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 95: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 98: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 99: South Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 102: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 103: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 111: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 112: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 114: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 115: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 118: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 119: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 122: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 123: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 131: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 134: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 135: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033

Figure 138: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 139: Oceania Market Attractiveness by Treatment, 2023 to 2033

Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 142: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 143: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 151: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 152: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 153: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 154: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 155: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 156: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033

Figure 158: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 159: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 160: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Bronchopulmonary Dysplasia Treatment Market

Published : July 2023

Healthcare

Cystic Fibrosis Therapeutics Market

Published : December 2022

Healthcare

Chronic Obstructive Pulmonary Disease (COPD) Market

Published : December 2022

Explore Healthcare Insights

View Reports

Progressive Pulmonary Fibrosis (PPF) Treatment Market